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Abstract
Background: Colorectal-cancer (CRC) research has greatly benefited from the availability of small animal tumor models.
Spontaneous and chemically-induced CRC models are widely used yet limited in their resemblance to human disease and
are often prolonged, not accurately repetitive, and associated with inflammatory side effects. In-situ murine or human
tumor implantation in the gastrointestinal tract of mice is extremely challenging, and limited by inter-animal variability and
procedure-related complications and mortality. As a result, in frequent studies CRC is implanted in distal sites, most
commonly the subcutaneous region, an approach that is greatly limited by the absence of normal gastrointestinal tumor
milieu and has substantial effects on tumor development.
Aims: In this study we aimed to develop a well-tolerated repetitive tool to study CRC in small animals by adapting the
murine colonoscopy system to serve as a platform for colonic sub-mucosal orthotopic implantation of human and murine
CRC tumor cells.
Results: We report the establishment of a novel small-animal CRC model that is minimally invasive, rapid, well-tolerated,
highly reproducible, and confers precise control of tumor number, location and growth rate. Moreover, we show that this
model uniquely allows the side-by-side induction of distinct genetically manipulated tumors, enabling the mechanistic
study of tumor interaction and cross-talk within the native intestinal microenvironment.
Conclusions: Employment of this new approach may represent a major technical advance for the in-vivo study of CRC.
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Introduction
Colorectal-cancer (CRC) is the second leading cause of cancer
mortality in many industrialized countries [1]. CRC models in
small animals have provided important tools for investigating the
underlying etiologic and pathophysiologic mechanisms of CRC
development and for the preclinical assessment of novel thera-
peutic modalities. Numerous murine CRC models have been
developed and described in the literature [2,3]. The main
approaches include mutant mice that develop spontaneous
tumors, treatment with a wide range of carcinogenic agents, with
or without induction of chronic inflammation, and ectopic or
orthotopic implantation of tumor cells.
Spontaneous CRC transgenic mouse strains closely imitate
human cancer syndromes, such as hereditary nonpolyposis
colorectal cancer (HNPCC) [4] and familial adenomatosis
polyposis (FAP) [5]. These models have been proven invaluable
for the study of the effects of known genetic alterations on the
disease course. However, many of these mouse models form
adenomas primarily in the small intestine, and are typically
associated with a slow growth rate and considerable inter-animal
variability [3] The Apc
Min/+ mouse strain was established based
on the results derived from a germ line mutagenesis study with N-
ethyl-N-nitrosourea combined with phenotypic screening [5].
Although this model is associated with the appearance of a large
number of benign adenomas in the small intestine, CRC tumors
develop in less than half of the animals. Nevertheless, treating
these mice with the carcinogenic agent azoxymethane (AOM)
substantially increases tumor incidence in the colons of these mice,
and this model has proven to be useful for studying the effects of
chemopreventive compounds [6,7].
Inducible CRC mouse models, on the other hand, are
commonly based on the use of various carcinogenic compounds,
such as azoxymethane (AOM), 1,2-dimethylhydrazine (DMH) and
others [2]. The chemically induced established tumors share many
of the histopathological characteristics of non-hereditary human
CRC [2,8]. Tumor development in these models has been
reported to be in the range of 30 weeks. Notably, combination
of the carcinogenic compound with chronic inflammation, such as
in the case of the AOM/dextran sodium sulfate (DSS) model, has
proven to shorten the latency time observed in the classical model
to about 10 weeks and to target induction of tumors mainly to the
distal colon [8,9]. These advantages, as well as its high potency,
simple mode of application, wide range of susceptibilities, and
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CRC research, and an excellent research tool to study early
carcinogenic events and to evaluate potential therapeutic ap-
proaches [2,8]. However, in this model tumors develop under the
environmental influences of chronic inflammation, a condition
that mimics inflammatory bowel disease (IBD)-associated CRC
but not the much more common sporadic human CRC.
Importantly, all CRC in- vivo models mentioned above suffer
from an inherent inability to control tumor numbers and growth
kinetics.
Several orthotopic murine CRC models have been described,
most of which require an operative approach for the injection or
implantation of the cancer cells into the colon or cecal layers
[10,11]. The complexity of the surgical procedure, resulting
trauma, procedure-related inflammation and mortality, severely
limit the value of these systems for the study of innate and adaptive
anti-tumor immune responses.
In humans, endoscopic examination of the colon is the most
important method for the discovery and follow-up care of CRC.
Recently, in vivo murine endoscopy has been developed allowing
high resolution imaging of the colon in living mice, and enabling
researchers to directly visualize and score pathologic tissue
changes in the colon [12,13] and in intra-abdominal organs
[14]. Moreover interventions such as repeatable biopsies of colon
lesions in living mice during the follow up period of an experiment
and their subsequent proteomic analysis have introduced new
powerful tools for CRC research [15].
We present here for the first time an adaptation of the murine
colonoscopy system and its employment for the establishment of a
novel orthotopic mouse model of CRC. This approach provides
an easy and straightforward solution to the technical limitations
associated with existing CRC models.
Results
Establishment of orthotopic mouse model of CRC
utilizing the murine colonoscopy system
Small animal endoscopy is considered today as the gold
standard tool for the surveillance of colonic inflammatory
disorders and CRC. In order to adapt this system for the purpose
of orthotopic implantation of CRC tumor cells into the colonic
sub-mucosa we have specially designed a hypodermic needle that
can pass through the endoscopic sheath working channel of the
Karl Storz Coloview miniendoscopic system. The hypodermic
needles were custom made according to our specification by
Cadence Inc. U.S.A., and are made from 8 inch long flexible
stainless flexible steel, with 30 gauge outer diameters, and a short
bevel at a 45 degree angel (Figure S1). This hypodermic needle
confers several design advantages; the flexible steel together with
needle’s dimensions alleviate the injection maneuver and allow the
smooth pass through the working channel and the Luer lock,
which is screwed on it to avoid air leakage. Moreover, the blunt
bevel allows injection into the sub-mucosa with reduced risk for
perforation or spilling of the injected material to the lumen. We
first examined the tissue distribution of injected reagents and
assessed the appropriate injection volume by injecting India ink
marking dye into the colonic sub-mucosa layer. An injection
volume of 50 ml gave the best combination of minimal leakage and
focal scattering of the ink beneath the epithelial layer (Figure 1A).
Flushing of the colonic lumen by applying saline through the
examination sheath of the endoscope confirmed the localization of
the injected ink beneath the epithelial layer (Movie S1).
Histological analysis confirmed that the India ink is retained
within the colonic lamina propria even 5 days following its
orthotopic injection (Figure S2A). Importantly, histological
analysis of mice injected with sterile Dulbecco’s Phosphate
Buffered Saline without calcium and without magnesium
(PBS
-/-) revealed a normal healthy colonic architecture at the
injection site confirming that this method is minimally invasive
(Figure S2B).
The MC-38 murine colon tumor is a grade III adenocarcinoma,
which was chemically induced in a female C57BL/6 mouse and
used sincethen as a transplantable mouse tumormodel [16]. To test
the feasibility of the orthotopic tumor implantation method, we
injected 1610
5 MC38 CRC tumor cells into the colonic sub-
mucosa of syngeneic C57BL/6 mice. Repetitive colonoscopy of
recipient mice revealed the progressive rapid development of the
tumor breaking into the gut lumen specifically at the injection site.
Endoscopic grading according to tumor size relatively to the
circumference of the colon,as established by Becker et al [12],
revealed progressive tumor growth from grade 1 at day 5 to grade 4
by day12 and reachinggrade 5, occupyingalmost the entire colonic
circumference, by only day 19 (Figure 1B, and Movie S2).
Hematoxyline and eosin (H&E) staining of histology sections
revealed a typical CRC architecture of the tumors with normal
adjacent mucosa and the projection of the tumor through the
epithelial layer into the lumen (Figure1C,D). Histological analysis
of colonic tissue isolated from mice subjected to orthotopic
implantation of 1610
5 MC38 CRC cells expressing GFP confirmed
the establishment of a small tumor within the lamina propria and
the penetration of tumor derived GFP
+ cells through the epithelial
layer already by day 5 (Figure 1E, F). Using this method, we were
also able to efficiently induce the formation of human CRC tumors
by implanting the human CRC cell-lines SW620, SW480, LS174T
and HT-29 into immuno-deficient NUDE or NOD/SCID
recipient mice (Figure S3A). Pathological assessment of orthotop-
ically established human CRC tumors using this model have
confirmed high similarity to CRC tumors isolated from human
patients (Figure S3B). Specifically, human CRC tumors formed by
the orthotopic implantation of LS174T and HT29 cells showed
histological features characteristic of colonic differentiated adeno-
carcinoma such as glandular structures lined with neoplastic
epithelium containing goblet cells and luminal necrotic material,
while the SW620 human CRC cells formed a tumor morphology
typical of poorly to undifferentiated carcinoma with nested and
diffused patterns and lack of tubular formation (Figure S3B).
Interestingly, both HT29 and LS174T human CRC cell lines were
formed from a primary adenocarcinoma of the colon, while the
SW620 was established from a lymph node metastasis.
In order to evaluate the growth kinetics of the CRC tumors
using this method we injected C57BL/6 mice with distinct
amounts of MC38 cells (10E3, 10E4 and 10E5 cells) and followed
the colonic circumference and developmental grade of established
tumors over time by colonoscopy (Figure 2A). The results
graphically summarized in figure 2B show that the tumor growth
kinetics was in direct correlation to the amount of injected cells
reaching colon circumference of 21% (+/24.22), 54.1% (+/27.0),
and 80% (+/27.2) 3 weeks following the injection of 10
3,1 0
4, and
10
5 MC38 cells, respectively. Statistical analysis comparing each
time point (1,2 and 3 weeks) for the different groups (10E3, 10E4
and 10E5 cells) confirmed significant differences (at least p,0.05)
in all the time points for percentage of colonic circumference as
well as for tumor grade. Exceptional was the comparison of tumor
grade between the 10E4 &10E5 groups at week 3 as most of the
tumors in these groups were already grade 5 that includes all
tumors above 50% of colonic circumference.
Collectively, we established here a new method for the efficient
orthotopic implantation of CRC tumors using murine endoscopy
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cells required for injection, and with an absolute control on
tumor’s incidence, location and growth kinetics.
Orthotopic implantation of genetically manipulated
CRC-tumor cells
One of the benefits of cancer implantation over spontaneous
developing tumor models is the ability to genetically modify the
established tumor. As a proof of principle, we injected BALB/c
mice with 1610
5 CT26 murine CRC cells, which had previously
been genetically manipulated to express luciferase. Whole body
bioluminescence optical imaging (Biospace Photon imager)
revealed the existence of a CRC tumor specifically around the
injection site that could be further semi-quantified according to its
emitted luminescence (Figure 3A). Notably, this approach may be
useful for the assessment of tumor burdens without the need to
sacrifice the mice. An additional genuine advantage of the
Figure 1. Orthotopic induction of CRC using the mouse colonoscopy system. (A) Colonoscopy image presenting colonic sub-mucosal
injection of India-ink dye in C57BL/6 mouse for the assessment of the appropriate injection volume and its distribution at the colonic lamina propria.
(B) Representative colonoscopy images indicating the progressive development of CRC tumor within the same C57BL/6 mouse following orthotopic
implantation of 1610
5 MC38 CRC cells from day 5, through day 12 to day 19. (C–D) Representative image of histology specimen stained with
hematoxyline and eosin (H&E) and isolated from colonic injection site at day 14 following injection of 1610
5 MC38 CRC cells. Magnifications: C- [x40],
D – [x100]. Note the boundary area between the tumor and the adjacent normal mucosa and the projection of the tumor through the epithelial layer
into the lumen. (E) Representative image showing H&E staining of histology specimen of murine-CRC tumor generated 5 days following orthotopic
implantation of MC38 CRC tumor cells into C57BL/6 mice (Magnification x40). (F) Fluorescent microscopic image showing GFP labeled tumor cells and
their dissemination through the epithelial layer toward the lumen (Magnification x100). Data are representative of three independent experiments.
doi:10.1371/journal.pone.0028858.g001
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adjacent yet distinct tumors in the same mouse, which were
genetically modified to over-express or silence genes of interest,
enabling their direct comparison in an identical host milieu. Using
a lentiviral reporter system, we transduced two distinct fluorescent
reporter genes into the MC38 cell line to establish the MC38-GFP
and MC38-RFP lines (Figure 3B upper left panel). Injection of
the MC38-GFP cells and adjacent to them the MC38-RFP cells
resulted in the co-formation of two genetically identical tumors
that vary only by their location and expression of the inserted
reporter genes (Figure 3B lower left panel and right panel).
Discussion
We describe herein a novel orthotopic murine CRC model
based on the adaptation of the commercially available miniendo-
scopy system that confers many advantages compared to known
murine CRC models. It is an easy to employ, minimally invasive,
and highly reproducible procedure that can be used on mice from
any genetic background. In this model both murine and human
CRC-tumors can be induced. The model allows also precise
control of tumor incidence and location within the colon. In
addition, this method enables absolute control on tumor growth
kinetics; it can be very rapid reaching grade 5 in 2 weeks following
the implantation of only 1610
5 tumor cells, or one can slow it by
injecting low number of cells. Importantly, this approach avoids
collateral damage and inflammation seen in many of the other
currently employed models. Moreover, it uniquely enables the
induction of genetically manipulated CRC-tumors and the
comparison of several distinct tumors established side-by-side in
the same mouse avoiding the inter-animal variability.
Ectopic subcutaneous implantation of tumor cell lines is widely
used as a research tool, especially for the assessment of cytostatic
therapeutic interventions [17]. However, ectopic implantation
disregards the complexity of the unique characteristic makeup of
the native microenvironment. Indeed, it has been well established
that the incongruent host stroma can affect tumorigenicity and cell
cycle regulation compared with implantation in the native tissue
bed [18,19]. The advantage of choosing an orthotopic approach is
of particularly importance for the intestinal milieu, which is the
home of unique immunological cellular and molecular entities that
resides in continuous interaction with the microbiota and
constitutive exposure to dietary antigens.
Performance of more then 200 orthotopic CRC implantations
utilizing this method has ensured that this model is well-tolerated
and highly reproducible. Yet, a possible complication of the
procedure is perforation of the colon and potentially leakage of air
and cells to the peritoneal cavity. Currently, in our hands, this
complication is rare, constituting less than 5 percent of all
procedures. Mortality during the procedure is extremely rare and
can happen due to the anesthesia or perforation. Tumor incidence
in surviving mice (95%) is 100%, always culminating in a sole
tumor development specifically at the injection site. Of note, the
use of a rigid scope allows access only to the distal half of the colon
and thus, restricts the orthotopic implantation by this approach to
this area.
Figure 2. Absolute control on growth kinetics of orthotopically induced tumors. (A) Representative colonoscopy images demonstrating
the correlation between amount of injected MC38 tumor cells and the size of the established CRC tumor 3 weeks following orthotopic tumor cell
implantation. (B) Graphs summarizing the growth kinetics, circumference percentage and developmental grade of colonic tumor in correlation to the
amount of injected MC38 CRC cells. Note the rapid establishment of grade 5 tumors already 2 weeks following implantation of only 1610
5 MC38-CRC
cells. Each group consisted of 5 mice.
doi:10.1371/journal.pone.0028858.g002
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many industrialized countries. Experiments done in small animals
have proven to be essential to the understanding of the
pathophysiology of the disease as well as for the preclinical
assessment of novel therapeutic modalities. Nevertheless, murine
CRC models are limited in their similarity to human disease. This
is especially true concerning the formation of CRC tumor
metastases. One notable disadvantage of CRC murine models is
the general lack of invasive and metastatic phenotype [2]. In the
AOM/DSS model infiltrative cords of epithelial cells were
described to breach the muscularis mucosa and reach also the
sub-mucosal lymphatic system, although very infrequently [20].
Similarly, we seldom witness local invasiveness of tumor-derived
cells, but never detect distal metastases using our approach. The
relatively rapid growth kinetics associated with our model, which
coerces the early sacrifice of implanted mice caring a grade 5 CRC
tumor, is probably becoming a disadvantage for induction of a
metastatic tumor. Indeed, even orthotopic implantation of human
CRC cells, known to be aggressively metastatic, failed to induce a
metastatic tumor. The common hindrance shared by murine CRC
models to establish a metastatic tumor may imply that the
intestinal murine milieu is not supportive of metastases formation.
Nevertheless, this can be turn into a desired model system for those
who wish to investigate the potential role of malignant genes. In
support of this, our system can be utilized to induce the formation
of genetically manipulated tumors in which we over-express or
silence genes of interest.
We believe that this new orthotopic CRC model represents a
major technical advance for the in-vivo study of CRC, and can be
particularly used to investigate new therapeutic modalities, tumor’s
genetics and growth mechanisms, and its interactions in the
context of the native intestinal microenvironment.
Methods
Ethics Statement
All animal studies were approved by the Tel Aviv Sourasky
Medical center ethical committee for animal studies and
conformed to the highest international standards of humane care
of animals in biomedical research. Committee approval number –
037_b3428_8.
Animals
8–10 week-old males C57BL/6, Balb C and Athymic nude mice
were obtained from Harlan biotech (Rehovot, Israel). 8–10 week-
old males NOD SCID mice were kindly provided by prof. Tsvee
Lapidot (Weizmann Institute of Science, Rehovot, Israel).
Athymic nude mice were sub-lethaly irradiated (450 rad) before
the orthotopic implantation of human CRC cell lines to eliminate
immuno-rejection. Animals had unrestricted access to food and
water, were housed in temperature and humidity-controlled
rooms, and were kept on a 12-hour light/dark cycle.
Colo-Rectal tumor cells
Murine C57BL/6 CRC tumor cells (MC38) were kindly
provided by Dr. Avi Eisenthal (Tel Aviv Sourasky Medical
Center). Luciferase stably- transfected murine CRC tumor cells
(CT26) were kindly provided by Prof. Lea Eisenbach (Weizmann
Institute of Science Rehovot, Israel). The human CRC tumor cell-
lines SW620, SW480 and LS174T were kindly provided by prof.
Figure 3. Orthotopic induction of distinct genetically manipulated CRC tumors. (A) Color-coded representative image of whole body
bioluminescence optical imaging of BALB/c mice 2 weeks following sub-mucosal injection of PBS
-/- (left mouse) or 1610
5 CT26 CRC tumor cells
expressing luciferase and 10 minutes following i.p injection of D-Luciferin. Note the luminescence emission specifically from the area of injected CRC
tumor cells (right mouse). (B) Upper left panel – fluorescent stereo-microscopic image overlaid on a photo graphic image of recipient C57BL/6 mouse
colon 3 weeks following its orthotopic injection with MC38 CRC cells that were genetically manipulated by lentiviral reporter system to express RFP,
magnification x10. Down left panel – colonoscopy image of C57BL/6 mouse colon following orthotopic implantation of 2 adjacent MC38 CRC tumor
cells; MC38-RFP (red arrow) and MC38-GFP (green arrow). Right panel - fluorescent stereo-microscopic image overlaid on a photo graphic image of
recipient C57BL/6 mouse opened colon 2 weeks following side-by-side orthotopic injection of MC38-RFP (distal) and MC38-GFP (proximal) CRC tumor
cells, magnification x10. Note the induction of 2 adjacent CRC tumors that differ only by the expression of the transduced reporter gene. Data are
representative of three independent experiments.
doi:10.1371/journal.pone.0028858.g003
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The HT-29 human CRC cell-line was the generous gift of Dr.
Isabel Zvibel (Tel-Aviv Sourasky Medical Center, Tel-Aviv,
Israel). All cell lines were maintained in 5% CO2 at 37uC in high
glucose DMEM medium supplemented with: 10% fetal bovine
serum, 1% of Penicillin streptomycin antibiotic solution, 1% L-
glutamin solution, and 1% sodium pyruvate solution.
Generation of MC38 CRC tumor cells expressing GFP or
RFP
MC38-GFP and MC38-RFP CRC tumor cells were generated
by transduction with pCSC-SP-PW-IRES-GFP/RFP lentiviruses
designed to express GFP or RFP with M.O.I of 50 (kindly
provided by Dr. Alon Chen, Weizmann Institute of Science
Rehovot, Israel). Subsequently, MC38 cells expressing GFP or
RFP were sorted to high purity using a high speed FACSAria II
sorter (Beckton-Dickinson).
Murine endoscopic system
We employed a high resolution mouse video endoscopic system
(‘‘Coloview system’’) previously described for murine endoscopic
procedures [12–14] which consists of a miniature endoscope (scope
1.9 mm outer diameter), a xenon light source, a triple chip camera,
and an air pump to achieve regulated inflation of the mouse bowel
(Karl Storz, Tuttlingen, Germany). The endoscopic procedure was
viewed on a color monitor and digitally recorded on tape.
Orthotopic colonic sub-mucosal implantation of CRC
cells
Mice were anesthetized using Ketamine/Xylazine. Sub-muco-
sal injections were accomplished using stainless flexible stainless
steel; 8 inch long, 30 gauge and 45 degree bevel hypodermic
needles custom made according to our specification (Cadence Inc.
U.S.A). The needle was inserted through Luer lock (So ¨llner,
GmbH) screwed on the working channel of the scope to avoid air
leakage. Subsequently, the scope was inserted into the mouse
colon and following its inflation the needle was brought through
the working channel to the scope’s front. The CRC cell
implantation procedure was performed by two coordinated
persons; one person was navigating the colonoscopy while the
other person was operating the injection maneuver. The injection
was performed under observation by a very gentle sub-mucosal
penetration with the open side of the bevel heading up in a flat
angle. A volume of 50 microliter CRC tumors cells was then
injected into the colonic sub-mucosa.
In-vivo imaging
To follow luciferase-expressing CT26 CRC tumor implantation
and growth in BALB/c mice, 50 ml D-Luciferin (30 mg/ml) was i.p
injected 10 minutes before and subsequently mice were inserted
into the closed dark chamber of the whole body cooled CCD
camera Photon Imager system (Biospace Lab, France). For in-vivo
visualization of GFP and RFP positive tumors Leica MZ16F
fluorescent stereomicroscopy system was used (Leica Microsys-
tems, Germany).
Histology
Tissues were fixed in 4% paraformaldehyde overnight at 4uC,
embedded in paraffin, serially sectioned (15 mm), and stained with
hematoxylin and eosin (Sigma).
Slides were observed using the Olympus BX51 microscope, and
image acquisition was conducted with the Olympus DP70 camera
and DP-Manager software.
CRC tumor growth kinetics
C57BL/6 mice were orthotopically sub-mucosal injected with
10
3,1 0
4,o r1 0
5 MC38 cells. The tumor’s colonic circumference
and developmental stage were monitored over time by colonos-
copy every week for 3 weeks following cell implantation.
Endoscopic grading was done according to tumor size relatively
to the circumference of the colon as established by Becker et al
[12]. In short, tumor size was graded as follows: Grade 1 (just
detectable tumor), Grade 2 (tumor covering up to 1/8 of colonic
circumference), Grade 3 (tumor covering up to 1/4 of the colonic
circumference), Grade 4 (tumor covering up to 1/2 of the colonic
circumference) and Grade 5 (tumor covering more than 1/2 of the
colonic circumference).
Statistical Analysis
The results were analyzed by one-way ANOVA and post
analysis with Bonferroni’s multiple comparison tests.
Supporting Information
Figure S1 Specially customized hypodermic needles
used to orthotopically inject the tumor cells into the
colonic sub-mucosa. The hypodermic needles are made from 8
inch long flexible stainless steel, with 30 gauge outer diameters,
and a short bevel at a 45 degree angel. Note that the needle is
inserted through the Luer lock that is subsequently screwed on the
working channel of the endoscope to avoid air leakage.
(TIF)
Figure S2 Sub-mucosal injections of PBS
-/- and India
ink. Representative images of histology specimens stained with
hematoxyline and eosin (H&E) and isolated from colonic injection
site at day 5 following injection of 50 ml of (A) India ink
(Magnification x40), (B) India ink (Magnification x100), (C)
PBS
-/-, note the normal healthy architecture of the colon. Data
are representative of three independent experiments.
(TIF)
Figure S3 Orthotopic induction of human CRC tumors
in immuno-deficient mice. (A) Representative images of
histology specimens stained with hematoxyline and eosin (H&E)
and isolated at day 35 following orthotopic injection (2610
5 cells
each) of the human CRC cell lines: SW620, SW480, LS174T and
HT29 into NOD/SCID or sub-lethally irradiated NUDE mice.
Data are representative of three independent experiments. (B)
Histo-pathological comparison between human CRC tumors
established by the orthotopic implantation of SW620, HT29,
and LS174T into immuno-deficient mice and human colorectal
adenocarcinoma.
(TIF)
Movie S1 Endoscopic live imaging of sub-mucosal
injection of India ink dye. Representative endoscopic video
imaging demonstrating the procedure of India-ink dye injection
into the colonic sub-mucosa of C57BL/6 mice using the mouse
colonoscopy system. Note the focal sub-epithelial distribution of
injected dye and its remaining following the colonic flushing.
(WMV)
Movie S2 Endoscopic live imaging of the progressive
localized growth of a CRC-tumor following its orthotop-
ic implantation. Endoscopic video imaging showing the
orthotopic implantation of CRC-tumor cells and the progressive
growth of the resulted tumor, specifically at the injection site and
at different time points within the same recipient.
(WMV)
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